Exelixis | EXEL - Interest Expense On Debt


Exelixis reported $23.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2023.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Akebia Therapeutics 364.15M 18.56M Sep/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bayer EUR 762M 267M Sep/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
Eisai JPY 1.43B 12M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
Exelixis USD 23.4M 3.9M Sep/2023
Genmab DKK 37M 28M Sep/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Sanofi EUR -25M 99.78M Dec/2025
Takeda JPY 123.63B 40.49B Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Xencor USD 7.66M 578K Sep/2025